STAT+: What a vote on Grail’s cancer detection test could mean for the company, patients, and regulators

Summary

Grail's stock surged following FDA posting of documents ahead of an advisory committee meeting on the company's blood-based cancer detection test. The meeting outcome could have significant implications for the company, patients, and regulatory precedent.